- Dr. Jeffrey Smith named Executive Vice President and Chief Healthcare Officer
- Dr. John Fann promoted to Senior VP, Process Sciences
- 7 new Vice Presidents appointed, underscoring motivation to management advancement
/EIN News/ — VANCOUVER, British Columbia, Jan. 04, 2024 (Globe NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology corporation producing a assorted pipeline of novel, multifunctional biotherapeutics to boost the normal of care for difficult-to-handle diseases, now declared sizeable additions to its management staff. These additions to the management group highlight Zymeworks’ dedication to nurturing and advancing interior expertise to critical management roles even though strengthening the capabilities and encounter of the corporation.
“At Zymeworks, we realize that our greatest asset is our people today. Elevating proficient individuals is a reflection of their robust performance for the company, our self confidence in their skills and the emphasis we spot on cultivating leaders from in just. As we go on to increase, their expanded roles will engage in critical pieces in advancing our ‘5 by 5’ development courses into the clinic in 2024 and 2025, scheduling to acquire our Progress preclinical systems into clinical research by 2027 and assisting to variety the vital collaborations and partnerships for our emerging products portfolio,” claimed Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
Leadership Staff
Dr. Jeffrey Smith has been promoted to Government Vice President and Main Health-related Officer, where by he will engage in a important purpose in foremost the medical advancement of our early-stage courses and overseeing our integrated global early-phase development group.
Dr. John Fann has been promoted to Senior Vice President, Method Sciences, where by he will proceed to enjoy a key function in supporting the progression of our new product or service candidates from preclinical studies into medical trials.
In addition, the subsequent individuals have been appointed to the management staff:
- Raquera Brown, Vice President, High-quality
- Bijal Desai, Vice President, Finance & Technique
- Lucas Donigian, Vice President, Company & Industrial Advancement
- Dr. Lindsey Foulkes, Vice President, Company Growth
- Cathie Graham, Vice President, Lawful
- Laura O’Connor, Vice President, Human Methods & DEI
- Dr. Joe Woolery, Vice President, Early-Phase Improvement (Americas)
“These excellent persons have regularly shown excellent management skills, dedication, and a deep knowing of our company goals and our dedication to individuals,” Mr. Galbraith extra. “After lessening the administration group to a smaller core team upon my appointment in early 2022, these new appointments reflect the added management assets necessary to regulate and progress our emerging solution portfolio.”
Extra data on the track record and working experience of these persons is available on the Company’s web site at www.zymeworks.com.
About Zymeworks Inc.
Zymeworks is a worldwide biotechnology organization fully commited to the discovery, growth, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a significant variance in the lives of men and women impacted by tricky-to-treat cancers and other conditions. The Company’s complementary therapeutic platforms and thoroughly built-in drug enhancement motor deliver the adaptability and compatibility to specifically engineer and acquire hugely differentiated antibody-centered therapeutic candidates. Zymeworks engineered and designed zanidatamab, a HER2-specific bispecific antibody employing the Company’s proprietary Azymetric™ technological know-how. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Prescribed drugs Eire Minimal (Jazz), granting just about every special legal rights to develop and commercialize zanidatamab in distinct territories. Zanidatamab is now being evaluated in multiple worldwide medical trials as a likely very best-in-course remedy for sufferers with HER2-expressing cancers. Zymeworks is promptly advancing a deep pipeline of products candidates based mostly on its knowledge and abilities in the two antibody drug conjugates and multispecific antibody therapeutics across many novel targets in indications that stand for spots of substantial unmet clinical need to have. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been more leveraged by way of strategic partnerships with world biopharmaceutical corporations. For data about Zymeworks, visit www.zymeworks.com and stick to @ZymeworksInc on X.
Cautionary Note Relating to Ahead-Searching Statements
This press release features “forward-on the lookout statements” or info inside of the meaning of the applicable securities legislation, which include Portion 27A of the Securities Act of 1933, as amended, and Segment 21E of the Securities Exchange Act of 1934, as amended. Ahead-wanting statements in this push release consist of, but are not limited to, statements about Zymeworks’ anticipations concerning implementation of its strategic priorities the timing of and final results of interactions with regulators Zymeworks’ medical progress of its product candidates and enrollment in its medical trials expectations regarding upcoming regulatory filings and approvals and the timing thereof likely therapeutic outcomes of zanidatamab and Zymeworks’ other solution candidates commercial likely of technology platforms and product candidates Zymeworks’ preclinical pipeline Zymeworks’ means to maintain current and execute new collaborations and partnerships and other details that is not historical facts. When utilized herein, terms these types of as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are supposed to detect ahead-looking statements. In addition, any statements or info that refer to expectations, beliefs, designs, projections, targets, effectiveness or other characterizations of long term situations or circumstances, including any underlying assumptions, are forward-on the lookout. All forward-on the lookout statements are primarily based on Zymeworks’ latest anticipations and several assumptions. Zymeworks thinks there is a reasonable basis for its expectations and beliefs, but they are inherently unsure. Zymeworks may possibly not understand its anticipations, and its beliefs may perhaps not demonstrate accurate. Precise effects could differ materially from people explained or implied by such ahead-seeking statements as a outcome of a variety of aspects, such as, without limitation: scientific trials may not show safety and efficacy of any of Zymeworks’ or its collaborators’ item candidates any of Zymeworks’ or its partners’ item candidates may possibly are unsuccessful in advancement, may not obtain expected regulatory approvals, or may well be delayed to a place wherever they are not commercially practical the effect of pandemics and other wellness crises on Zymeworks’ company, study and medical growth options and timelines and success of functions, like effects on its scientific demo sites, collaborators, and contractors who act for or on Zymeworks’ behalf inability to maintain or enter into new partnerships or strategic collaborations regulatory agencies may perhaps impose supplemental necessities or delay the initiation of clinical trials the effect of new or switching regulations and laws marketplace disorders and the other hazards described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (a copy of which may well be acquired at www.sec.gov and www.sedar.com).
Despite the fact that Zymeworks believes that these forward-searching statements are affordable, there can be no assurance they will confirm to be proper. Investors should really not position undue reliance on ahead-wanting statements. The above assumptions, dangers and uncertainties are not exhaustive. Ahead-seeking statements are produced as of the date hereof and, apart from as may be expected by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-wanting statements to mirror new info, long run functions or conditions, or to mirror the occurrences of unanticipated situations.
Trader inquiries:
Shrinal Inamdar
Director, Trader Relations
(604) 678-1388
[email protected]
Media inquiries:
Diana Papove
Senior Director, Company Communications
(604) 678-1388
[email protected]